Search research articles
Contact Us
Filters
Showing results (211-220 of 251) with videos related to
Page
of 26
Sort By:
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The Journal of Urology
|
September 10, 2021
Reply by Authors
Lauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
The Journal of Urology
|
September 10, 2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort
Lauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
European Urology Oncology
|
November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
Omar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi, William Kevin Kelly, Hua Ma, et al.
European Urology
|
December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Jun Luo, Gerhardt Attard, Steven P Balk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Nallasivam Palanisamy, Jun Yang, Peter D A Shepherd, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 30, 2016
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer
Fortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, et al.
Science Signaling
|
May 25, 2017
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li, Styliani Karanika, Guang Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer
Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Page
of 26
Search research articles
Search
Showing results (211-220 of 251) with videos related to
Sort By:
Page
of 26
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The Journal of Urology
|
September 10, 2021
Reply by Authors
Lauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
The Journal of Urology
|
September 10, 2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort
Lauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
European Urology Oncology
|
November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
Omar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi, William Kevin Kelly, Hua Ma, et al.
European Urology
|
December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Jun Luo, Gerhardt Attard, Steven P Balk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Nallasivam Palanisamy, Jun Yang, Peter D A Shepherd, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 30, 2016
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer
Fortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, et al.
Science Signaling
|
May 25, 2017
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Likun Li, Styliani Karanika, Guang Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer
Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Page
of 26